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Protein homeostasis is critical to biological processes that are
fundamental to cancer cell survival. Therefore, targeting the
regulation of protein production and destruction, particularly
factors that mediate proliferation and other hallmark character-
istics of malignancy, has been a major focus of cancer research.
Recently, it has become widely appreciated that the orderly
destruction of cell cycle regulatory proteins is critical to the con-
trol of cellular processes associated with cancer. The ubiquitin-
proteasome pathway (UPP), which processes more than 80%
of all cellular proteins, is the principal mechanism for degrada-
tion of proteins, including those involved in cell cycle regulation
(Adams, 2002a). Accordingly, the proteasome has emerged as
an attractive target for cancer therapy. This article focuses on
proteasome inhibition as an anticancer strategy and on the
development of bortezomib, the first-in-class proteasome
inhibitor to enter clinical practice.
The ubiquitin-proteasome pathway
Proteins are targeted for recognition and for subsequent degra-
dation by the proteasome via the attachment of multiple ubiqui-
tin molecules. The 26S proteasome is a 2,000 kDa multisubunit
cylindrical complex comprised of a 20S core catalytic compo-
nent (the 20S proteasome) capped at one or both ends by a
19S regulatory component (Figure 1) (Adams, 2003). The 19S
subunit recognizes and binds the polyubiquitinated protein and
cleaves the ubiquitin chain from the protein substrate. The pro-
tein is then unfolded and fed into the 20S core, and the ubiquitin
molecules are recycled.The 20S core is composed of 4 stacked
rings: 2 outer rings (α rings) and 2 internal rings, termed β rings,
in which proteolysis occurs. Each β ring consists of 7 subunits
containing 3 active enzymatic sites termed trypsin-like, chy-
motrypsin-like, and post-glutamyl peptide hydrolase-like (cas-
pase-like), after enzymes that show similar activity or specificity
(Almond and Cohen, 2002; Adams, 2003). Within the 20S core,
proteins are progressively degraded to small, 3- to 25-amino-
acid peptides (Nussbaum et al., 1998).
Research has shown that the UPP is integral to mecha-
nisms underlying carcinogenesis and metastasis, including cell
cycle regulation, apoptosis, and angiogenesis (King et al.,
1996; Adams 2004). The proteasome has a direct role in allow-
ing the cell to progress through the cell cycle by degrading cell
cycle regulatory proteins, and an indirect role by regulating the
availability of transcriptional activators, such as nuclear factor
(NF)-κB (see Table 1 and discussion below).
Proteasome inhibitors
The most important proteasome inhibitors fall into 5 classes:
peptide aldehydes, peptide vinyl sulfones, peptide boronates,
peptide epoxyketones (epoxomycin and eponomycin), and β-
lactones (lactacystin and its derivatives), based on the pharma-
cophore that reacts with a threonine residue in the active site of
the proteasome (reviewed in Kisselev and Goldberg, 2001).The
biological activities of the epoxyketones have not been exten-
sively studied; of the others, all but the peptide boronates exhibit
properties that render them unsuitable for clinical development.
Reasons to reject a proteasome inhibitor for future clinical
development have included metabolic instability (Adams et al.,
1998; Adams et al., 2000), lack of enzyme specificity, and irre-
versible binding to the proteasome (reviewed in Almond and
Cohen, 2002).
Nonetheless, the peptide aldehydes and lactacystin have
been useful in the study of effects of proteasome inhibition in
cancer cell lines and in tumor xenografts. Key findings include:
(1) cytotoxicity selective for transformed, as opposed to normal,
cells (An et al., 1998; Orlowski et al., 1998; Masdehors et al.,
2000); (2) additive effects when a proteasome inhibitor is com-
bined with other anticancer agents (Cusack et al., 2001), includ-
ing cytotoxicity in transformed cells at doses lower than those
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Figure 1. A schematic of the 26S proteasome
The 26S proteasome, a 2,000 kDa multiprotein complex, is comprised of a
proteolytically active 20S core particle that is capped by 1 or 2 19S regula-
tory particles. The 19S regulatory units recognize ubiquitinated proteins and
control access to the proteolytic core. Reprinted from Adams (2003) with
permission from Cancer Treatment Reviews.
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required when the agents are used individually (Guzman et al.,
2002); (3) sensitization of cell lines resistant to radiotherapy
(Pajonk et al., 2000) or chemotherapy (Ogiso et al., 2000; Desai
et al., 2001); and (4) induction of apoptosis in cells overexpress-
ing Bcl-2 (An et al., 1998). In addition, in proliferating,
subconfluent, endothelial cell cultures, the peptide aldehyde
proteasome inhibitor can induce apoptosis at a concentration
340-fold lower than that required in quiescent cells, grown to
confluence and contact-inhibited, suggesting that proteasome
inhibition may affect tumor growth by inhibiting angiogenesis
(Drexler et al., 2000).
Peptide boronic acid analogs
Because peptide boronic acids inhibit serine proteases such as
chymotrypsin by mimicking substrate binding at the active site
(Kettner and Shenvi, 1984; Weber et al., 1995), it was postulated
that they might inhibit the proteasome by binding to the
chymotrypsin-like site in the 20S core (Adams et al., 1998).
Dipeptidyl boronates synthesized to test this hypothesis showed
high potency, high specificity for the chymotryptic site, and
reversible activity (Almond and Cohen, 2002; Adams, 2003).
Thirteen boron-containing compounds were screened for anti-
cancer activity in the National Cancer Institute (NCI) panel of 60
cancer cell lines. One compound, PS-341, later designated
bortezomib (Figures 2 and 3), was potent, inhibited the enzyme
at nM concentration (Ki 0.6 nM), was active against a broad
range of cancer cell lines, including non-small cell lung, colon,
central nervous system, melanoma, ovarian, renal, prostate, and
breast cancers, and had a unique cytotoxicity profile, compared
with the NCI’s historical file of 60,000 compounds (Adams et al.,
1999).Thus, it was selected for intensive study.
Bortezomib
Mechanism of action
Numerous proteins are degraded by the proteasome, so multi-
ple cellular processes are affected by proteasome inhibition
(see Table 1). Therefore, the activity of bortezomib in different
cancers probably involves a variety of molecular mechanisms.
Extensive preclinical research has been conducted with borte-
zomib to elucidate its mechanism of action and to examine its
activity, both as a single agent and in combination with other
anticancer modalities, in a wide variety of solid tumor and
hematologic cancer cell lines and tumor models.
In cell culture, bortezomib induces apoptosis in both hema-
tologic and solid tumor malignancies, including myeloma
(Hideshima et al., 2001), mantle cell lymphoma (Pham et al.,
2003), and non-small cell lung (Ling et al., 2003), ovarian
(Frankel et al., 2000), pancreatic (Shah et al., 2001; Bold et al.,
2001), prostate (Adams et al., 1999; Frankel et al., 2000), and
head and neck (Sunwoo et al., 2001) cancers.The mechanisms
by which bortezomib induces apoptosis are unclear, although
the stabilization of pro- and antiapoptotic proteins, including
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Table 1. Selected processes affected by proteasome activity in normal and cancerous cells
Process Proteins degraded by the proteasome Reference
Cell cycle control Cyclins A, B, D, E; cyclin-dependent kinase Adams, 2004
inhibitors (p27, p21WAF1/CIP1); cdc25 phosphatase
Oncogenic transformation C-fos, C-jun, N-myc Adams, 2002a; Almond and Cohen, 2002
Tumor suppression p53 Adams, 2002a; Adams, 2004
Apoptosis Bax Li and Dou, 2000
Protein turnover 80% of cellular proteins Adams, 2002a; Adams, 2004
NF-κB activation IκB Karin et al., 2002
Proinflammatory cytokines (TNF-α, IL-1, IL-6) Karin et al., 2002 ; Adams, 2004
Cell adhesion molecules (ICAM-1, VCAM-1) Adams, 2002a; Adams, 2004
Stress response enzymes (COX-2, NOS, 5-lipoxygenase) Karin et al., 2002; Adams, 2004
Antiapoptotic factors (Bcl-2, IAP,TRAIL) Almond and Cohen, 2002; Adams, 2004; 
Zhang et al., 2004
Proangiogenesis factors (VEGF, GRO-α) Sunwoo et al., 2001
ER stress (URP) Lee et al., 2003
Figure 2. The structure of the dipeptidyl boronic acid proteasome inhibitor
bortezomib
Reprinted from Adams (2003) with permission from Cancer Treatment
Reviews.
Figure 3. Cross-sectional view of the bortezomib binding site in the protea-
some. 
Bortezomib interacts with a threonine residue on the β subunit that confers
chymotryptic proteolytic activity. Reprinted from Adams (2003) with per-
mission from Cancer Treatment Reviews.
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cyclin-dependent kinase inhibitors (e.g., p21 and p27) and
tumor suppressors (e.g., p53) has been associated with protea-
some inhibition (Shah et al., 2001; An et al., 1998; MacLaren et
al., 2001). Proteasome inhibition has also been demonstrated
to interfere with the unfolded protein response (UPR), thereby
causing endoplasmatic reticulum stress (ER-stress) and
increased apoptosis (Lee et al., 2003). Additionally, bortezomib
sensitizes resistant solid tumor cells to TNF-like apoptosis,
inducing ligand (TRAIL)-induced apoptosis, most likely by
increasing the levels of death receptors (DR) DR4 and DR5
(Zhang et al., 2004).
Proteasome inhibition may induce apoptosis or increase
sensitivity to apoptosis by shifting the balance between pro- and
antiapoptotic signals (see Adams, 2003, for discussion). The
involvement of regulatory proteins in apoptosis differs according
to cell type. For example, p53 expression was essential for pro-
teasome inhibitor-induced apoptosis in mammary epithelial
cells (MacLaren et al., 2001), whereas it was irrelevant in PC-3
prostate cancer cells, which are p53 null (Adams et al., 1999). In
the latter, bortezomib caused G2/M cell cycle arrest and apop-
tosis (Adams et al., 1999). These in vitro cytotoxic effects of
bortezomib were affirmed in a murine xenograft model of
human prostate cancer in which bortezomib reduced tumor
growth by about 60% (p < 0.05) compared with vehicle treat-
ment (Adams et al., 1999).
One molecule with a central role in mediating many of the
effects of proteasome inhibition is the transcriptional activator
NF-κB. Known to be involved in inflammatory and immune
responses, NF-κB and its signaling pathways were also recent-
ly implicated in tumor development (Karin et al., 2002). Under
normal conditions, NF-κB is bound to its inhibitor IκB, and tran-
scriptional activation of genes by NF-κB is suppressed. In
response to cellular stresses, IκB is degraded by the protea-
some and NF-κB is released, activating transcription of genes
for growth factors, stress response enzymes, cell adhesion mol-
ecules, and apoptosis inhibitors (reviewed in Karin et al., 2002)
(Table 1). Activation of NF-κB may also occur in response to
chemotherapy and radiation and confer resistance (Wang et al.,
1999). In contrast, bortezomib inhibits NF-κB activation through
proteasome inhibition (Hideshima et al., 2001; Cusack et al.,
2001; Hideshima et al., 2002), potentially providing a rationale
for the use of bortezomib in cells that constitutively express NF-
κB or in combination with chemotherapy and radiation.
However, inhibition of NF-κB activation does not completely
explain the anticancer activity of bortezomib. Hideshima and col-
leagues (2002) compared the effects of an IκB kinase inhibitor,
PS-1145, and bortezomib in multiple myeloma cells. Although
both PS-1145 and bortezomib blocked NF-κB activation, borte-
zomib completely suppressed cell proliferation, whereas PS-
1145 inhibited cell proliferation by only 20% to 50%.
The tumoricidal activity of bortezomib involves other mech-
anisms as well. Cancer progression and metastasis depend on
tumor angiogenesis, as well as on adhesion factors and growth
factors. Several preclinical studies report that bortezomib caus-
es inhibition of tumor angiogenesis, consistent with the selec-
tive effect of proteasome inhibition on proliferating endothelial
cells. Bortezomib markedly decreased microvessel density in
murine and human xenograft head and neck tumors and in
human prostate tumors implanted in mice (Sunwoo et al., 2001;
Williams et al., 2003). Decreased vascular endothelial cell
growth factor secretion and high levels of endothelial cell apop-
tosis were also seen in the prostate tumor model (Williams et
al., 2003). Decreased tumor angiogenesis was also observed in
tumors from mice implanted with multiple myeloma xenografts
(LeBlanc et al., 2002).
In some cancers, such as multiple myeloma, bortezomib
alters the microenvironment such that it is less susceptible to
tumor cell growth. In multiple myeloma, tumor cells bind to bone
marrow stromal cells (BMSCs), triggering them to secrete inter-
leukin (IL)-6 through activation of NF-κB. Bortezomib decreases
myeloma cell binding to BMSCs, reducing NF-κB-mediated
synthesis of IL-6 by the stroma (Hideshima et al., 2001).
Bortezomib has shown the ability to have additive activity
with other therapies through several mechanisms as observed
in vitro and in animal models. Moreover, bortezomib has con-
ferred a chemosensitizing effect that allows the use of lower
doses of other antineoplastic therapies to achieve a tumoricidal
effect at least equivalent to that of higher monotherapy doses.
This effect has been observed using bortezomib with:
• doxorubicin, melphalan, or dexamethasone in multiple
myeloma cell lines (Mitsiades et al., 2003; Hideshima et
al., 2001; Ma et al., 2003)
• irinotecan or radiation therapy in colon cancer
xenografts (Cusack et al., 2001; Russo et al., 2001)
• gemcitabine in pancreatic cancer xenografts (Bold et
al., 2001)
• daclizumab (an anti-IL-2Rα antibody) in a model of
adult T cell leukemia (Tan and Waldmann, 2002)
• radiation therapy, cyclophosphamide, and cisplatin in a
mouse mammary tumor model (Teicher et al., 1999).
Bortezomib has also been shown to confer renewed sensitivity
to chemotherapeutic agents in cell lines that previously devel-
oped resistance to their cytotoxic effects. Specifically, in cell
lines previously resistant to doxorubicin, melphalan, mitox-
antrone, and dexamethasone, bortezomib was able to restore
the therapeutic activity of these agents (Hideshima et al., 2001;
Mitsiades et al., 2003).
Differential sensitivity of neoplastic cells to bortezomib
Selective toxicity of proteasome inhibitors toward transformed
cells has also been observed with bortezomib (Hideshima et al.,
2001). In general, proteasome inhibition tends to induce apop-
tosis in proliferating cells while being protective in some but not
all quiescent cells (Drexler, 1997). One of the more notable
exceptions is the potent induction of apoptosis by proteasome
inhibitors in malignant B cell chronic lymphocytic leukemia cells,
which are largely quiescent (Masdehors et al., 2000). The
increased sensitivity of cancer cells to proteasome inhibition
may be partially related to the dysregulation of molecules that
drive the cell cycle, such as the cyclin-dependent kinases, and
high proliferation rates observed in neoplastic cells. However,
bortezomib induces cell death in prostate cancer cells with a
very low growth fraction (Frankel et al., 2000). Nonetheless,
because cancer cells generally are defective in cell cycle check
points, they may be particularly susceptible to the stress
imposed by proteasome inhibition (see discussion in Almond
and Cohen, 2002).This may explain why, in a human plasmacy-
toma xenograft mouse model, bortezomib significantly inhibited
tumor growth with low systemic toxicity, despite the observation
that the degree of proteasome inhibition was greater in normal
tissues than in tumors (LeBlanc et al., 2002).
Clinical trials
Bortezomib was the first proteasome inhibitor to enter clinical
trials. Two phase I trials, one in solid tumors and one in hemato-
logic malignancies, have been published and establish that
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bortezomib could be administered with acceptable and man-
ageable toxicity (Aghajanian et al., 2002; Orlowski et al., 2002).
In the solid tumor trial, a major response was observed in a
patient with refractory non-small cell lung carcinoma, and the
investigators suggested that bortezomib should be evaluated
further, perhaps in combination with other agents in future trials
(Aghajanian et al., 2002). Encouraging activity, especially in
multiple myeloma and malignant lymphoma, was seen in the
phase I trial in hematologic malignancies (Orlowski et al., 2002).
A pivotal phase II trial of bortezomib was conducted in 202
patients with relapsed and/or refractory multiple myeloma who
had progressed after a median of 6 previous therapeutic regi-
mens. Using modified criteria of the European Group for Blood
and Marrow Transplantation (Bladé et al., 1998), a 35%
response rate was observed in 193 evaluable patients, includ-
ing 4% with complete response (myeloma protein undetectable
by electrophoresis and immunofixation), 6% near-complete
response (myeloma protein detectable only by immunofixation),
18% partial response, and 7% minimal response (Richardson et
al., 2003). Using criteria of the Southwest Oncology Group, 18%
of patients experienced clinical remission (≥75% paraprotein
reduction). The incidence of grade 4 adverse events was
relatively low, and most could be managed with standard
approaches (Richardson et al., 2003). Among all 202 patients,
the median time to progression was 7 months while they were
receiving bortezomib, as compared with 3 months while receiv-
ing the last treatment before entering the study. These results
are encouraging, in view of the fact that complete responses are
rare in patients with multiple myeloma that has become refrac-
tory to prior regimens (Richardson et al., 2003). A positive ther-
apeutic response to bortezomib was not influenced by the type
of multiple myeloma or by the type or number of previous thera-
pies (Richardson et al., 2003).
In May 2003, the US Food and Drug Administration
approved bortezomib for the treatment of patients with multiple
myeloma who have received at least 2 prior therapies and who
have demonstrated disease progression on their last therapy. In
addition, bortezomib was approved in April 2004 by the CPMP
for use in the European Union. Ongoing clinical trials are inves-
tigating the use of bortezomib in an earlier myeloma patient
population and in combination with other antineoplastic thera-
pies (Adams, 2002b). Promising early clinical results in non-
Hodgkin’s lymphoma (Goy et al., 2003; O’Connor et al., 2003)
and in several solid tumors (Aghajanian et al., 2002; Albanell et
al., 2003; Appleman et al., 2003) have been reported. These
findings support current investigations that are elucidating the
efficacy and safety of bortezomib in the treatment of various
types of malignancies and identifying optimal parameters for its
use, particularly in combination with other agents.
Preclinical and clinical studies have validated the hypothe-
sis that the proteasome is a viable therapeutic target. It is espe-
cially encouraging that after little more than one decade,
proteasome inhibition has moved from hypothesis to clinical
application in the treatment of cancer.
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